The emergence of cell, gene and tissue-based therapies has transformed modern medicine ,offering life-changing treatments for previously untreatable diseases. These Advanced Therapy Medicinal Products (ATMPs) promise unprecedented benefits but also bring new, complex safety challenges.

Traditional pharmacovigilance (PV) frameworks, designed for conventional drugs, are not always equipped to handle the unique risks of ATMPs. As a result, auditing safety systems for these innovative products requires a tailored, forward-looking approach.

At Q&V, we help organisations navigate these challenges through expert pharmacovigilance audits and compliance support designed specifically for advanced therapies.

1. The Unique Safety Landscape of Advanced Therapies

Unlike traditional medicines, ATMPs often involve living cells, genetic material or tissue manipulation, making their safety profile dynamic and sometimes unpredictable.

Key challenges include:

• Long-term or delayed adverse effects that may emerge years after treatment
  
• Individualised manufacturing and dosing, which complicate standard safety tracking
  
• Complex supply chains involving specialised storage and transport conditions
  
• Limited patient populations, restricting the ability to detect safety signals early
  

Auditors must therefore assess not only the pharmacovigilance system’s compliance with GVP standards, but also its ability to capture and manage complex, long-term safety data.

2. Regulatory Expectations for ATMP Pharmacovigilance

Regulatory agencies such as the MHRA and EMA have issued specific guidance for ATMPs, emphasising the need for proactive safety monitoring.

A compliant PV system should include:

• A dedicated Risk Management Plan (RMP) addressing long-term safety concerns
  
• Post-authorisation safety studies (PASS) tailored to the product’s mechanism
  
• Traceability systems linking each product to its source and recipient
  
• Effective communication channels with hospitals, transplant centres and patients
  

Q&V’s audit methodology ensures all regulatory expectations are reviewed, documented, and benchmarked against the latest GVP modules and ATMP-specific requirements.

3. Auditing the Pharmacovigilance System for ATMPs

Auditing advanced therapy safety systems requires both scientific understanding and regulatory precision.

Key audit focus areas include:

• Signal detection and risk evaluation processes for rare, complex events
  
• Data management and integrity in handling long-term patient records
  
• Qualified Person for Pharmacovigilance (QPPV) oversight and communication pathways
  
• Vendor and site compliance, including hospitals, clinics and manufacturing partners
  
• Governance of registries and follow-up studies for patient monitoring
  

Auditors must ensure all safety data ,from laboratory to clinic ,is traceable, accurate and securely maintained throughout the product’s lifecycle.

4. Building a Risk-Based Audit Strategy

Given the evolving nature of ATMPs, a risk-based approach to auditing is essential.
This involves:

• Prioritising audits based on product complexity and patient exposure
  
• Evaluating the adequacy of long-term follow-up plans
  
• Assessing third-party agreements to ensure responsibilities are clearly defined
  
• Ensuring the PV system remains adaptable as new safety information emerges
  

Q&V’s auditors apply a structured, risk-based framework that balances regulatory compliance with scientific understanding ,ensuring robust and future-ready PV systems.

5. Q&V’s Role in Supporting ATMP Compliance

At Q&V, we specialise in helping pharmaceutical and biotechnology companies strengthen their pharmacovigilance frameworks for advanced therapies. Our expert teams provide:

• Independent GVP audits tailored to ATMP operations
  
• Risk management and compliance assessments
  
• Audit readiness and inspection support
  
• Guidance on PSMF, RMP and long-term safety documentation
  

With a strong focus on both quality and ethical responsibility, Q&V ensures your advanced therapy programmes meet the highest standards of patient safety and regulatory confidence.

Advanced therapies represent the future of personalised medicine ,but their promise can only be realised through rigorous safety oversight.

By integrating pharmacovigilance audits, risk-based compliance strategies, and ethical data governance, organisations can ensure that innovation never comes at the cost of patient safety.

Q&V is your trusted partner in building resilient, compliant, and ethical pharmacovigilance systems for the next generation of medical innovation.

Partner with Q&V ,where compliance meets care.